Trial · NCT04738487
Adverse events1,196
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,196
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab/Vibostolimab First Course | 145 | 593 | 182 |
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab First Course | 117 | 610 | 162 |
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab/Vibostolimab Second Course | 0 | 1 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab Second Course | 1 | 3 | 1 |
| other | Hyperthyroidism | Endocrine disorders | Pembrolizumab/Vibostolimab First Course | 39 | 593 | 50 |
| other | Hyperthyroidism | Endocrine disorders | Pembrolizumab First Course | 29 | 610 | 32 |
| other | Hyperthyroidism | Endocrine disorders | Pembrolizumab/Vibostolimab Second Course | 0 | 1 | 0 |
| other | Hyperthyroidism | Endocrine disorders | Pembrolizumab Second Course | 0 | 3 | 0 |
| other | Hypothyroidism | Endocrine disorders | Pembrolizumab/Vibostolimab First Course | 56 | 593 | 74 |
| other | Hypothyroidism | Endocrine disorders | Pembrolizumab First Course | 67 | 610 | 78 |
| other | Hypothyroidism | Endocrine disorders | Pembrolizumab/Vibostolimab Second Course | 0 | 1 | 0 |
| other | Hypothyroidism | Endocrine disorders | Pembrolizumab Second Course | 1 | 3 | 1 |
| other | Constipation | Gastrointestinal disorders | Pembrolizumab/Vibostolimab First Course | 65 | 593 | 76 |
| other | Constipation | Gastrointestinal disorders | Pembrolizumab First Course | 59 | 610 | 66 |
| other | Constipation | Gastrointestinal disorders | Pembrolizumab/Vibostolimab Second Course | 0 | 1 | 0 |
| other | Constipation | Gastrointestinal disorders | Pembrolizumab Second Course | 0 | 3 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Pembrolizumab/Vibostolimab First Course | 51 | 593 | 68 |
| other | Diarrhoea | Gastrointestinal disorders | Pembrolizumab First Course | 59 | 610 | 84 |
| other | Diarrhoea | Gastrointestinal disorders | Pembrolizumab/Vibostolimab Second Course | 0 | 1 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Pembrolizumab Second Course | 0 | 3 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04738487/events